Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 27 Mar 2023 |
| Transactions in connection with share buy-back program | 20 Mar 2023 |
| Transactions in connection with share buy-back program | 13 Mar 2023 |
| Transactions in connection with share buy-back program | 13 Mar 2023 |
| Transactions in connection with share buy-back program | 6 Mar 2023 |
| Genmab A/S has published its Articles of Association | 1 Mar 2023 |